Modifying ER Protein Trafficking via 4-PBA Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating cancer and enhancing immunotherapy are limited by the stringent intracellular retention of GRP94, which hinders the extracellular secretion of GRP94:antigen complexes, crucial for eliciting an immune response.
Innovation Solution
Administration of 4-PBA and its analogs, such as methoxy-PBA, 3-PPA, 5-PVA, hydroxy-PPA, and tolyl-BA, which bind to COPII proteins, promoting the extracellular secretion of GRP94:antigen complexes by disrupting ER retention mechanisms, thereby increasing their levels and facilitating immune recognition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If GRP94 is retained in the endoplasmic reticulum through COPII-mediated retention mechanisms, then GRP94 maintains its intracellular function, but extracellular secretion of GRP94:antigen complexes is hindered
Solution Approach 1:
The patent applies parameter changes by modifying the trafficking signal sequence of GRP94 (e.g., mutating the KDEL retention signal to KDQL or other variants) to alter its interaction with COPII proteins. This changes the retention parameter from strong (wild-type) to reduced (mutant), enabling extracellular secretion while maintaining sufficient intracellular function. The parameter change is achieved through amino acid substitution in the trafficking signal region.
Solution Approach 2:
The patent uses an intermediary approach by introducing modified trafficking signal sequences that act as mediators between intracellular retention and extracellular secretion. These modified signals (e.g., KDQL, KPQL, KQQL) serve as intermediate states that allow partial retention and partial secretion, enabling GRP94 to function both intracellularly and be secreted extracellularly with antigens.
2Productivity
If GRP94 is secreted extracellularly, then immune response against cancer cells or viral antigens is enhanced, but intracellular retention and function are compromised
Solution Approach 1:
The patent applies parameter changes by creating mutant GRP94 variants with modified trafficking signals that change the secretion parameter from low (wild-type) to high (mutant). These variants (e.g., GRP94-KDQL, GRP94-KPQL) are engineered to have altered COPII interaction strength, increasing extracellular secretion to enhance immune response while monitoring intracellular function retention.
Solution Approach 2:
The patent applies partial action by using mutant trafficking signals that provide partial retention and partial secretion rather than complete retention. The modified signals (e.g., KDQL) allow sufficient intracellular GRP94 to maintain chaperone function while enabling enough secretion to elicit immune response, achieving a balance between the two competing requirements.
3Quantity of substance
If COPII retention mechanisms are disrupted to increase GRP94 secretion, then extracellular GRP94:antigen complexes increase, but ER quality control may be compromised
Solution Approach 1:
The patent applies parameter changes by modifying the trafficking signal sequence parameter rather than disrupting the entire COPII retention mechanism. This targeted parameter change (amino acid substitution in the signal sequence) selectively alters GRP94 secretion while leaving the general ER quality control machinery intact, allowing selective modification of one protein's trafficking without compromising overall ER function.
Solution Approach 2:
The patent uses an intermediary approach by introducing modified trafficking signal sequences that act as mediators between ER quality control and extracellular secretion. These modified signals allow GRP94 to escape retention selectively while maintaining interaction with COPII components, serving as an intermediary that enables secretion without completely disrupting the retention system or quality control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly enhances cancer and viral immunotherapy by increasing extracellular GRP94 levels, leading to a robust immune response against cancer cells or viral antigens, with potential for increased antibody production and reduced tumor size.
Implementation Method 1
4-PBA, the compound of Formula I, and/or the 4-PBA analog binds to COPII protein
Data Source
AI summary
The present disclosure provides compositions and methods for modifying endoplasmic reticulum trafficking of proteins. Also disclosed herein are methods for treating cancer and/or enhancing cancer or viral immunotherapy in a subject by increasing the extracellular secretion levels of GRP94 in the subject. Such methods comprise administering to the subject an effective amount of 4-PBA and/or a 4-PBA analog selected from among methoxy-PBA, 3-PPA, 5-PVA, hydroxy-PPA, hydroxy-PBA, and tolyl-BA.